Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.

ABSTRACT:

SUBMITTER: Perl AE 

PROVIDER: S-EPMC5572576 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature